AZD1222 Clinical Trials Resume in the UK

September 13, 2020
BioPharm International Editors

Clinical trials for AZD1222 coronavirus vaccine resume in the UK as per guidance by MHRA.

It has been announced, in a Sept. 12, 2020 press release, that the clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, are to be resumed in the United Kingdom. Resumption of the trial follows confirmation of safety by the Medicines and Healthcare products Regulatory Agency (MHRA).

The clinical trials of AZD1222 were halted voluntarily on Sept. 6, 2020 as a result of an incidence of illness in one of the UK trial participants. A standard review process was then implemented, allowing for safety data to be analyzed by independent committees and international regulators, such as MHRA.

No further medical information has been disclosed by AstraZeneca and the University of Oxford; however, all trial investigators and participants will be updated with the relevant information. Additionally, AstraZeneca reported in the press release that all relevant information will be disclosed on global clinical registries to comply with clinical trial and regulatory standards.

Clinical trials that were taking place outside the UK are still halted until the health authorities of those countries have issued guidance that the trials can be resumed.

Source: AstraZeneca